- Home
- EVG vs IPSC Comparison
EVG vs IPSC Comparison
Compare EVG & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- IPSC
- Stock Information
- Founded
- EVG 2005
- IPSC 2019
- Country
- EVG United States
- IPSC United States
- Employees
- EVG N/A
- IPSC N/A
- Industry
- EVG Investment Managers
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- EVG Finance
- IPSC Health Care
- Exchange
- EVG Nasdaq
- IPSC Nasdaq
- Market Cap
- EVG 149.5M
- IPSC 149.1M
- IPO Year
- EVG N/A
- IPSC 2021
- Fundamental
- Price
- EVG $11.04
- IPSC $1.22
- Analyst Decision
- EVG
- IPSC Strong Buy
- Analyst Count
- EVG 0
- IPSC 4
- Target Price
- EVG N/A
- IPSC $13.00
- AVG Volume (30 Days)
- EVG 49.4K
- IPSC 462.0K
- Earning Date
- EVG 01-01-0001
- IPSC 11-05-2024
- Dividend Yield
- EVG 8.68%
- IPSC N/A
- EPS Growth
- EVG N/A
- IPSC N/A
- EPS
- EVG N/A
- IPSC N/A
- Revenue
- EVG N/A
- IPSC $2,684,000.00
- Revenue This Year
- EVG N/A
- IPSC $244.52
- Revenue Next Year
- EVG N/A
- IPSC $27.73
- P/E Ratio
- EVG N/A
- IPSC N/A
- Revenue Growth
- EVG N/A
- IPSC 7.88
- 52 Week Low
- EVG $9.13
- IPSC $1.14
- 52 Week High
- EVG $10.86
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- EVG 40.36
- IPSC 37.50
- Support Level
- EVG $11.03
- IPSC $1.14
- Resistance Level
- EVG $11.36
- IPSC $1.50
- Average True Range (ATR)
- EVG 0.16
- IPSC 0.14
- MACD
- EVG -0.02
- IPSC -0.00
- Stochastic Oscillator
- EVG 23.96
- IPSC 18.65
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.